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ABSTRACT
Background
Plasmodium falciparum merozoite surface protein 3 is a malaria vaccine candidate that was
identified, characterised, and developed based on a unique immuno-clinical approach. The
vaccine construct was derived from regions fully conserved among various strains and
containing B cell epitopes targeted by human antibodies (from malaria-immune adults) that are
able to mediate a monocyte-dependent parasite killing effect. The corresponding long
synthetic peptide was administered to 36 volunteers, with either alum or Montanide ISA720 as
adjuvant.
Methods and Findings
Both formulations induced cellular and humoral immune responses. With alum, the
responses lasted up to 12 mo. The vaccine-induced antibodies were predominantly of
cytophilic classes, i.e., able to cooperate with effector cells. In vitro, the antibodies induced an
inhibition of the P. falciparum erythrocytic growth in a monocyte-dependent manner, which
was in most instances as high as or greater than that induced by natural antibodies from
immune African adults. In vivo transfer of the volunteers’ sera into P. falciparum–infected
humanized SCID mice profoundly reduced or abrogated parasitaemia. These inhibitory effects
were related to the antibody reactivity with the parasite native protein, which was seen in 60%
of the volunteers, and remained in samples taken 12 mo postimmunisation.
Conclusion
This is the first malaria vaccine clinical trial to clearly demonstrate antiparasitic activity by
vaccine-induced antibodies by both in vitro and in vivo methods. The results, showing the
induction of long-lasting antibodies directed to a fully conserved polypeptide, also challenge
current concepts about malaria vaccines, such as unavoidable polymorphism, low antigenicity,
and poor induction of immune memory.
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The development of a malaria vaccine holds considerable
promise, but has been limited by major conceptual and
practical difﬁculties [1]. In view of the imprecise relevance of
animal models [2], we have chosen a path where all critical
observations leading to go/no-go decisions in the develop-
ment process were based, as much as possible, on observa-
tions made in Plasmodium falciparum–infected individuals[3].
Merozoite surface protein 3 (MSP3) is an antigen identiﬁed
by a novel approach in which the protection, which could be
passively transferred by IgG from protected African adults
into naı ¨ve, infected individuals [4], was used to identify a
mechanism of defence [5,6]. The latter, called antibody-
dependent cellular inhibition (ADCI), was used to screen a P.
falciparum genomic expression library and, eventually, to
identify MSP3 as the target of protective antibodies in
humans [7]. This is not the way most other vaccine candidates
have been selected [1].
The decision to move from preclinical investigations into
clinical trials with an MSP3-based vaccine resulted from
convergent data from a series of studies that strengthened the
association between protection and antibodies directed to
this particular antigen, namely, (a) that anti-MSP3 antibodies,
either naturally occurring or elicited by immunisation, could
achieve parasite killing in the presence of normal monocytes,
either in vitro [7,8] or (b) in vivo by passive transfer in P.
falciparum–infected immunocompromised mice [8,9]; (c) sim-
ilar results were obtained with a human recombinant anti-
MSP3 monoclonal antibody (M. Dziegiel and PD, unpublished
data); (d) IgG3 anti-MSP3 antibodies were associated with
protection in the two African villages of Dielmo and Ndiop
[8,10], and in the village of Oo-do in Asia [11]; (e) IgG3 anti-
MSP3 antibodies were associated with an improved prognosis
of drug-treated cerebral malaria [10]; and (f) strong protec-
tion was induced by MSP3 in Cebidae monkeys against a P.
falciparum challenge [12]. Additional arguments were that (g)
the C terminus of the antigen containing the epitopes
targeted by ADCI is fully conserved [13,14]; and (h) all proteic
and peptidic formulations tested were immunogenic, and
particularly a synthetic polypeptide covering three B cell
epitopes targeted by protective antibodies (CO, et al.,
unpublished data) [8].
We therefore decided to initiate a phase-I clinical trial
aimed at assessing safety and immunogenicity, using a
preparation of the long synthetic peptide (LSP) formulation
derived from the conserved region of MSP3 (MSP3-LSP)
produced under Good Manufacturing Practices. The con-
struct included three B cell epitopes and four T-cell epitopes,
identiﬁed in lymphocytes from exposed populations [8]. The
clinical trial was designed as a single site, open, randomised,
dose-escalating phase-I study in six groups of six naive
European volunteers, with two ajduvants, alum and Monta-
nide.
Besides safety and immunogenicity, which are the object of
a separate report [15], the planned trial analysis included a
number of biological assays aimed at providing an early
indication of the antiparasitic effect of the immune responses
induced. This included determinations of antibody reactivity
with the parasite protein (and not only the epitopic peptides),
duration of the antibody response, isotype proﬁle (partic-
ularly with respect to the induction of IgG1 and IgG3 classes
that can cooperate with monocytes in the ADCI assay [6]),
and, importantly, the biological activity of the antibodies
against P. falciparum as determined in vitro by ADCI and in
vivo by passive transfer in P. falciparum–infected SCID mice
[9].
The MSP3 vaccine was safe and highly immunogenic [15].
The results of the functional tests of the induced immune
responses are reported here.
Methods
Clinical Trial
The conditions for production of the MSP3 LSP under
Good Manufacturing Practices, quality assurance, quality
control, pharmacotoxicity, enrolment of the 36 volunteers,
and clinical and laboratory investigations, have been de-
scribed in detail elsewhere [15]. Brieﬂy, 36 volunteers with no
previous history of malaria were recruited for the study and
were randomly allocated to six treatment groups, with no
major imbalance in sex and age distributions. The study was
approved by the Institutional Review Board. Immunisations
were performed subcutaneously at months 0, 1, and 4.
Samples for immunological studies were taken 1 mo after
each immunisation, i.e., at months 1, 2, and 5. The MSP3 LSP
polypeptide was adjuvated either by Montanide ISA720
(SEPPIC, Paris, France) or adsorbed onto aluminium hydrox-
ide (alum; Berna Biotech, Bern, Switzerland). The dose-
escalating trial design included four dosages with Montanide
of 10 lg, 20 lg, 30 lg, or 100 lg of polypeptide, and two
groups with alum with either 30 lg or 100 lg of polypeptide.
In view of the very strong immunogenicity of the molecule,
and of local DTH reactions mostly with Montanide (in four of
the ﬁve cases recorded), the original protocol of immunisa-
tion was amended by the clinicians [15] so that the ﬁnal
regimens received by the six different treatment groups were
as follows: for Montanide (each polypeptide dose given in
micrograms), 10–10–10, 30–30–10, 100–10–10, and 20–20–20,
and for alum, 30–30–30 and 100–10–10. Thirty volunteers
underwent the full immunisation schedule. The correspond-
ing 90 sera collected at months 0, 5, and 12 were used in the
present study.
Immunological Analysis
Lymphocyte and antibody assays. Immune responses were
assessed using as antigen the MSP3-LSP peptide, as well as the
four epitopic peptides MSP3a, MSP3b, MSP3c, and MSP3d as
described [8,15].
The conditions of lymphocyte and antibody assays have
been described in detail [15]. The proliferative responses of
the volunteers’ lymphocytes were assessed in sextuplicate
wells, incubated for 6 d at 37 8Ci n5 %C O 2 in the presence of
MSP3-LSP at 10 lg/ml and pulsed with 1 lCi of
3H-TdR [15].
Results were expressed as stimulation indices calculated as
the ratio of the mean
3H-thymidine incorporation (cpm) in
the presence and the absence of antigen. The interferon
gamma (IFN-c) concentration in pooled supernatants from
sextuplicate wells was evaluated by ELISA (Elipair, Diaclone,
France), according to the manufacturer’s instructions, and
expressed as the mean 6 standard deviation (SD). Antibodies
were determined by ELISA as described [16, 17], using, along
with positive and negative controls, test samples diluted 1/100
in microtitre plates (Nunc Maxisorp, Naperville, Illinois,
United States) coated with MSP3-LSP at 7 lg/ml in PBS and
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as arbitrary units deﬁned as the ratio of the test sample OD to
the mean OD þ3 SDs of 20 individual healthy blood donor
samples. In consecutive individual experiments with a set of
40 sera, the results expressed in arbitrary units varied by less
than 5% from one experiment to the other. Anti-MSP3-LSP
isotypes were determined as described previously [17], and
results expressed as individual ratios of pre- and postimmune
plasma sample OD. The cytophilicity ratio was calculated as
the sum of cytophilic divided by noncytophilic classes ([IgG1
þ IgG3]/[IgG2 þ IgG4 þ IgM]).
Reactivity with parasite proteins. Mature schizont-stage
proteinsofP.falciparum(3D7clone)wereextractedinLaemmli
samplebuffer,submittedtoelectrophoresis,andtransferredto
nitrocellulose as described [7]. Nitrocellulose strips were
incubated with a 1:100 dilution of each volunteer’s serum,
washed,andincubatedwithalkalinephosphatase-labelledanti-
human IgG diluted 1/5,000, and the reaction revealed using
NBT and BCIP (Promega, Madison, Wisconsin, United States).
Each of the three samples (months 0, 5, and 12) from each
volunteer were testedsimultaneously, and month 5 and month
12sampleswerestudiedsidebysidewitharecombinanthuman
anti-MSP3 antibody (M. Dziegiel, et al., unpublished data) used
as positive control. The intensity of reactivity was classiﬁed as
negative, positive (þ), or strongly positive (þþ).
Afﬁnity studies. The binding strength of the MSP3-speciﬁc
antibodies was evaluated by a modiﬁed ELISA protocol
carried out in the presence of increasing concentrations of
the chaotropic thiocyanate ion NH4SCN (0.5 M, 1 M, 1.5 M, 2
M, 3 M, and 4 M). Resistance to increasing thiocyanate
stringency conditions has been previously reported to
provide an estimate of avidity [16,18,19]. An afﬁnity index
(AI) representing the molarity of NH4SCN that induced a
50% reduction of the maximal antibody signal in ELISA
(obtained in the absence of the chaotropic agent) was used to
compare the different sera. Ten sera from the village of
Dielmo, Senegal, and ten from the village of Oo-do, Myanmar,
were used as positive controls [11,17].
Biological Antiplasmodial Activity of the Antibodies
Elicited by Immunisation
In vitro monocyte-mediated effect of antibodies (ADCI
assay). PBMCs were obtained from cytopheresis samples of
healthy European blood donors without previous exposure to
malaria, isolated by density gradient separation on J PREP
(TechGen, Les Ulis, France), aliquoted in decomplemented
ABþ serum (Institut Jacques Boy, Reims, France) with 10%
DMSO (Sigma-Aldrich, St. Louis, Missouri, United States) at a
ﬁnal concentration of 4 3 10
6 monocytes/vial, and cryopre-
served until use (A. Jafarshad, unpublished data). By relying on
cryopreserved monocytes from cytopheresis, we could employ
in the present study cells from only three donors, and thereby
minimize inter-donor monocyte variability of the assay as
comparedtopreviouslyemployedtechniques[6,8].Thedonors
were selected based on low or absent direct effect of the
monocyte preparation on P. falciparum cultures (  15 %),
Following thawing, cells were diluted 1 in 4 in HBSS without
calcium and magnesium (Gibco, San Diego, California, United
States) buffered with 20 mM Hepes (Gibco). Viability of
monocytes, determined with Trypan blue and by nonspeciﬁc
esterase(Sigma-Aldrich)staining[6],wasusually90–95%.Cells
were added to 96-well ﬂat-bottom culture plates (TPP,
Trasadingen, Switzerland) at a rate of 2 3 10
5 monocytes per
well, incubated for 1 h at 37 8C and 5% CO2, and washed three
times with RPMI, thereby separating nonadherent mononu-
clear cells from the attached monocytes.
Decomplemented volunteer sera were studied in duplicate
wells at a concentration of 1:10 (vol/vol) in complete RPMI
medium, together with normal human monocytes and P.
falciparum (3D7 clone) culture at 2% haematocrit and 0.5–1%
starting parasitaemia, in a ﬁnal volume of 100 ll, as described
[6]. Negative and positive controls added to each ADCI
culture plate included puriﬁed IgG from European blood
donors with no history of travel to malaria-endemic areas,
and puriﬁed IgG from the pool of African sera employed for
in vivo passive immunisation [20], both at a concentration of
2 mg/ml (corresponding to about 10% of African serum IgG
concentration). At 48 and 72 h of culture, 50 ll of complete
RPMI medium was added per well. After 96 h of growth,
parasitaemia was determined by microscopic counting of
more than 50,000 red blood cells on Giemsa-stained thin
smears [6,7]. Final parasitaemia was in the range of 8%–15%.
Experiments in which the growth of the parasite was not
optimal (  10-fold over the 96-h period) were excluded. Each
plate included normal human IgG from non-malaria-exposed
French blood donors as a negative control, African hyper-
immune pooled IgG (effective in passive transfer experiments
in Thai patients) as a positive control [20], and test serum,
each with and without monocytes. The speciﬁc growth
inhibition (SGI) index, which takes into account the potential
inhibitory effect of either monocytes alone or serum alone,
was calculated as follows: SGI ¼ 1   [(percentage of
parasitaemia with monocytes and test IgG/percentage of
parasitaemia with test IgG)/(percentage of parasitaemia with
monocytes and normal IgG/percentage of parasitaemia with
normal IgG)] 3 100. For comparison between several ADCI
assays, the SGI obtained with each test serum was expressed as
the percentage of the SGI recorded with the African IgG pool
included in each plate. Each serum was tested three times in
duplicate, and results were expressed as the arithmetic mean
of the individual SGI obtained in each experiment. Hence a
total of 270 individual ADCI assays were performed. Since the
mode of calculation of the SGI can result in a negative value
when the test serum has a growth-promoting activity, but also
when the monocytes have a growth-promoting effect, without
effect of the test serum, negative SGI values are shown as
‘‘ADCI non-effective,’’ i.e., with an SGI ¼ 0 in the results
section. The ADCI assays were also performed and the SGI
was determined with two other parasite strains, in addition to
3D7 parasite clone, i.e., using the Uganda Palo Alto parasite
strain for all sera post immunisation (months 5 and 12) and
using the Thai T23 strain for all sera collected at month 5.
Based on previous experience, the threshold of positivity of
the ADCI assay was considered to be 30% or greater of the
positive control.
In vivo passive transfer of antibodies in P. falciparum–
infected SCID mice. The procedure employed was similar to
that previously described [9]. It was approved by the ethical
committee for animal experiments at the Pasteur Institute.
Non-adaptive defences of immunocompromised BXN mice
were modulated by reducing the number of tissue macro-
phages and by controlling the number of blood polymorpho-
nuclear neutrophils using intraperitoneal (IP) injections of 0.2
ml of dichloromethylenediphosphonate (Cl2MDP) encapsu-
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antibody NIMP-R14, every 4 d. Synchronized ring forms of
clone 3D7 in AB
þRhD
þ erythrocytes were injected IP, and
uninfected AB
þRhD
þ erythrocytes were supplemented in the
same manner every 3–4 d. Daily thin blood ﬁlms drawn from
the tail vein were used to monitor the development of
parasitaemia. Total human PBMCs were isolated by Ficoll-
Hypaque (Sigma) and human monocytes were positively
selectedwithCD14
þmagneticbeads(MACkit,MiltenyiBiotec,
Bergisch Gladbach, Germany). Purity was determined by non-
speciﬁc esterase staining (mean . 98%) and viability was
estimated by Trypan blue exclusion (mean . 85%).
This recently developed model remains challenging and
time-consuming, and it has a substantial failure rate. Para-
sitaemia can sometimes resume spontaneously in a propor-
tion of animals; however, this always occurs early, during the
ﬁrst week, usually by days 4–8. In contrast, when the
parasitaemia reaches day 10, it persists for weeks or even
months, and is interrupted only by the accidental death of the
animal or by the administration of effective drugs or
antibodies (Text S1) [8,9,21]. For the assessment of volunteer
antibodies, when the parasitaemia was found to either
increase or remain stable for at least 12 d postinfection, 3 3
10
6 puriﬁed human monocytes were engrafted IP in each
mouse. Human monocyte density in mouse blood was
monitored by FACS analysis using the anti-CD14 monoclonal
antibody, revealed by goat anti-mouse IgG-AlexaFluor 188
(Molecular Probes, Eugene, Oregon, United States), diluted 1/
500. The same mouse was sequentially injected IP with either
monocytes alone or serum alone, followed by monocytes plus
volunteer’s sera in a volume of 200 ll injected IP. This
amount of human serum results in a ;40-fold dilution of the
volunteer’s serum in mouse blood as determined by ELISA
titration 24 h postinjection, and catabolism led to a
progressive disappearance of the transferred Ab within 7 d.
Statistical Analysis
Univariate analysis was performed using either nonpara-
metric tests (Mann-Whitney U-test and Spearman rank
correlation) or a parametric test (unpaired t-test for
comparison of mean values). Fisher’s exact test was used for
contingency table analysis. Multivariate analysis using regres-
sion was done using JMP software from SAS Institute (Cary,
North Carolina, United States). For longitudinal analysis of
12-mo samples, the individuals’ previous results at 5 mo were
taken into account by covariance analysis.
Results
The safety and tolerance of the vaccine were satisfactory,
particularlywithalum,andarereportedindetailelsewhere[15].
Induction of Strong T and B Cell Responses
Immunogenicity is summarized in Figure 1. The scheme of
immunisation and sampling is shown in Figure 1A.
T cell proliferative responses (Figure 1B) were detected in 29
outof30volunteerswhocompletedtheimmunisationschedule,
and were as high as with the potent stimulator tetanus toxoid.
Stimulation indices were almost maximal from the ﬁrst
immunisation, even at the lowest dose injected, remaining high
over thefollow-up.Notably, responseswereasstrongwith alum
aswithMontanide,whichcontrastswithresultsobtainedinmice
and in South American primates, in which alum had been
ineffective with this (unpublished data), as with other vaccines
[22]. The strongest responses were directed to MSP3 peptides a,
b, and c, in the alum groups [15]. Similarly, IFN-c secretion in
response to stimulation by the MSP3-LSP was in the range
10,000–50,000 IU after the ﬁrst immunisation, as high as that
inducedbytetanustoxoid(Figure1B).Incontrast,interleukin4
production was nonsigniﬁcant [15].
Antibody responses as measured by ELISA were detected in
77% (23/30) of the volunteers. They increased progressively
over time (Figure 1C), despite a moderate decrease between
the second and the third injections [15], which was followed
by a strong boost. Titres induced by alum-adjuvated MSP3
were lower after the second immunisation than those induced
by Montanide [15]; however, they reached similar levels after
the third immunisation (Figure 1C).
Western blots (WBs) showed the induction of antibodies
able to react with the MSP3 48-kDa parasite protein in most
but not all volunteer sera [15]. Amongst the ELISA-positive
individuals, 22% did not react with the parasite protein by
WB, accordingly 78% were positive by WB (Figures 1D and 2).
Thus there were qualitative differences among volunteers in
the types of antibodies elicited. The overall 60% reactivity to
native proteins among immunised volunteers (18/30) indi-
cates that the vaccine formulation is not yet optimal.
Isotype studies revealed that the dominant subclasses were
IgG1 followed by IgG3, i.e., the cytophilic antibodies that can
cooperate with blood monocytes in the ADCI effect (see
Figure 1E). Hence, the antibody isotype balance was very
different from that of infected travellers and children from
endemic areas, whose responses are predominantly non-
cytophilic, and was essentially similar to that of adults from
endemic areas who have reached a state of protection
[10,11,23]. Finally, the isotyping revealed differences in titre
between the alum and Montanide groups that were not
apparent using anti-total-IgG (see Figure 1C), possibly due to
differences in afﬁnity or titre of antibodies directed to each
subclass in the anti-IgG.
Epitope mapping revealed other differences in vaccine-
induced, as compared to parasite-induced, responses. Where-
as natural exposure to the parasite induced antibodies to
each of the three B cell epitopes (b, c, and d) included in the
LSP [8], LSP immunisation induced antibodies to peptides
MSP3c and MSPd, but almost none to MSP3b, except in one
volunteer [15]. This may be related to the conformation of the
synthetic as compared to the native parasite protein. Notice-
ably, anti-MSP3c and anti-MSP3d antibodies have been found
to be of equal functional importance in defence to those
directed to the MSP3b peptide [8].
Afﬁnity, indirectly evaluated by a modiﬁed ELISA, indi-
cated that the vaccine adjuvated by alum induced antibodies
with signiﬁcantly higher afﬁnity than those elicited by the
Montanide-adjuvated vaccine (mean AI 6 1 SD, 2.03 6 0.47
and 1.62 6 0.33, respectively; p ¼ 0.0068 by unpaired t-test),
and that the afﬁnity increased between the second and third
immunisations (AI ¼ 1.64 and 2.03, respectively, in the alum
group; p ¼ 0.02.). The values obtained by artiﬁcial immunisa-
tion are of similar magnitude to those observed among
protected African or Asian adults (mean AI ¼ 1.64 6 0.49 in
66 protected individuals in Oo-do) [11].
Vaccine-Induced Antibodies Have Strong Antiplasmodial
Activity
The sera were studied using the bioassays previously found
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and which were also at the origin of the identiﬁcation of the
vaccine candidate.
In vitro assays. The antibody-monocyte cooperative effect,
as assayed by ADCI (Figure 2A), is expressed as a percentage
of the positive control used in each plate—the pool of
African IgG able to passively transfer protection in naive
recipients [20]. Preimmunisation samples were negative in
the assay (SGI   10%; summarized in Figure 3). MSP3
immunisation elicited antibodies with a parasite-killing effect
as strong as that from protected African adults or even
stronger in some volunteers, reaching up to two times the
potency of African immune IgG (see Figure 2A). Moreover,
the few parasites remaining at the end of the ADCI assays
performed with the volunteer antibodies were pycnotic, i.e.,
presumably dead. Alum was at least as effective as Montanide
at eliciting antibodies effective at reducing parasite growth.
Antiparasite activity correlated with the ability of the
antibodies to react with the parasite protein: all but one of
the WB-positive sera exerted a profound ADCI effect, i.e.,
above the threshold value of 30% ADCI (see Figure 2A). The
SGI recorded using two other parasite isolates, UPA and
FCIP150, were almost identical (the mean SGI values as
compared to the parasite clone 3D7 varied by 6 5.1 and
5.4%, respectively,), in agreement with the amino-acid
sequence conservation of the antigen among P. falciparum
isolates. At the serum concentrations employed, no signiﬁ-
cant direct merozoite invasion inhibitory effect was recorded
at any time point (Figure 3).
In vivo passive transfer. A subset of nine volunteers’ sera
were studied individually by passive transfer experiments into
immunocompromised mice grafted with human red blood
cells in which a sustained P. falciparum parasitaemia can be
obtained [9]. The effect of total African immune IgG, and of
afﬁnity-puriﬁed anti-MSP3b and anti-MSP3d antibodies has
been documented in this demanding but demonstrative
model [8,9]. All types of parasitaemia established for more
than 10 d were found previously to be stable, and were
interrupted only by administration of antimalarial drugs
effective against the parasite strain grafted in mice (but not
against drug-resistant parasites) [21] or by ADCI-effective
antibodies (but not by ADCI-ineffective antibodies) [8,9],
indicating that a decrease in parasitaemia was not accidental,
but resulted from these interventions.
Mice with steady parasitaemia were injected ﬁrst with
normal monocytes, then a subset with the preimmunisation
serum (serum month 0), to ascertain the absence of direct
effect of the individual components used in the experiment.
This was followed by the injection of the postimmunisation
serum (serum month 5). The WB-positive antibodies elicited
by immunisation were found to exert a strong parasite-killing
Figure 1. Immunogenicity of the MSP3-LSP in Volunteers Receiving the
Vaccine Adjuvated by Montanide or Alum
(A) Scheme of immunisation (arrows) and of sampling (plain circles).
Samples for immunoassays were taken 1 mo after each immunisation.
(B) Lymphoproliferative responses (bars) and IFN-c secretion (*), 6 SD, as
compared to controls. PHA, phytohemagglutinin; TT, tetanus toxoid. IFN-
c values for TT and PHA are those obtained using month 5 samples.
(C) Mean ELISA IgG titres to the MSP3-LSP at various time points during
and after immunisation (months 1, 5, and 12 after the first immunisation).
(D) Proportion of WB-positive individuals in each group at different time
points 6 95% confidence intervals.
(E) Isotype distribution of antibodies measured in ELISA with IgG
subclass-specific secondary antibodies (data from samples collected at
month 5).
In each graph, the increasing grey colour corresponds to increasing
immunisation doses, e.g., for Montanide (unhatched bars) from left to
right, 10–10–10, 20–20–20, 30–30–10, 100–10–10, and for alum (hatched
bars) 30–30–30 and 100–10–10.
DOI: 10.1371/journal.pmed.0020344.g001
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well as sera from WB-negative individuals, were not effective
(Figure 4B), even when injected twice (Figure 4B, volunteers 8
and 21), demonstrating the speciﬁcity of the in vivo results.
Kineticstudieshaveindicatedthatthe200llofseruminjected
IP resulted in a ;40-fold dilution of the volunteers’ antibodies
in mouse serum. It is remarkable that relatively low concen-
trationsoftheantibodieselicitedbyimmunisationcouldresult
in the observed profound antiparasite effect. Indeed, the
passivetransferofvolunteers’antibodies,positiveinADCIand
in WB, induced a fast subsequent decrease of the parasitaemia
(e.g., Figure 4A, volunteers 14 and 18) and in some animals a
full clearance of the parasites (e.g., volunteer 16, not shown in
Figure 4A). This contrasts with African IgG, which shows a
profound but subtotal effect (i.e., does not clear all parasites),
butisinkeepingwiththatofanti-MSP3puriﬁedantibodies[9].
Results at 12 Months: Long-Lasting Secretion of
Antibodies Able to Kill P. falciparum in the Alum Group
Analysis of 12-mo samples revealed several important
features. T lymphocyte responses remained unusually high in
t h ea l u mg r o u p ,a sh i g ha sa f t e rt h es e c o n do rt h i r d
immunisations, whereas they decreased slightly in the Mon-
tanide group (see Figure 1B). ELISA assays of antibodies
directed to the synthetic peptide showed an expected drop in
titres, particularly in the Montanide group (see Figure 1C),
although this decrease did not reach signiﬁcance. The number
of WB-positive individuals also decreased markedly in this
group (see Figures 1D and 2B), whereas all WB-positive
individuals in the alum group remained positive at 1 y. In
addition, possiblydue to a maturation of immuneresponses in
relationtothestrongThelper(Th)effect,WBswerepositivein
threeindividualsthatwerenegativeatmonth 5(seeFigures1D
and 2B). This resulted in a signiﬁcant difference in the ability
to react with the parasite protein between the alum and the
Montanide groups (p ¼ 0.018). Finally, the mean afﬁnity of
antibodies at 1 y also remained higher in the alum group than
in the Montanide group (AI¼1.77 and 1.35, respectively).
In agreement with these ﬁndings, ADCI assays showed a
substantial decrease of the parasite-killing effect of Monta-
nide-induced antibodies as they became unable to react with
thenative protein(seeFigures2B and3). Conversely,therewas
a persistence of a strong ADCI effect in the WB-positive sera
fromthealumgroup (seeFigure2B). Therelationship ofADCI
activity with recognition of parasite native proteins in WB was
signiﬁcant in either the Montanide or alum group (p¼0.00021
and 0.041, respectively, by unpaired t-test). Finally, the overall
difference in ADCI activity between the Montanide and alum
groups was signiﬁcant (17.2% and 66.3%, respectively; p ¼
0.0016). Therefore, analysis of 1-y samples showed a marked
advantage of alum over Montanide, particularly in terms of
biological activity of the antibodies.
Figure 2. In Vitro Antiparasitic Effect of the Volunteers’ Antibodies in ADCI Assay
Shown are results obtained with volunteers’ serum samples collected either at month 5 (A) or at month 12 (B), as compared to the African immune IgG
pool able to transfer clinical protection in humans (dark bars, pool of immune African globulin-positive control). Each bar represents the mean value
obtained with each volunteer serum, in three separate experiments 6 SD. The results from WB assays (performed with months 5 and 12 samples side
by side with a positive control) are shown below those of the ADCI assay for each individual volunteer and are expressed as either negative ( )o r
positive (þ or þþ). For each group, the increasing grey colour corresponds to increasing immunisation doses, e.g., from left to right, Montanide
(unhatched bars) 10–10–10, 20–20–20, 30–30–10, and 100–10–10, and for alum (hatched bars) 30–30–30 and 100–10–10. SGI values 30% or greater are
considered positive. Dotted line indicates the threshold of positivity of the ADCI assay.
DOI: 10.1371/journal.pmed.0020344.g002
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MSP-3 Induces IgG that kill P. falciparumThis was conﬁrmed by in vivo passive transfer experiments
of12-moserumsamplesinimmunocompromisedmice(Figure
4C).SimilarresultswereobtainedusingthreeWB-positivesera
from the alum group and were ascertained twice (e.g., serum
from volunteer 21 in two distinct animals, Figure 4C). Finally,
intheabsenceofhumanmonocytes,thevolunteers’antibodies
werenoteffective(controlserum12moalone;volunteer21),in
agreement with previous observations with African afﬁnity-
puriﬁed antibodies [9].
Antiparasite Activity is a Function of Qualitative and
Quantitative Parameters of T and B Cell Responses
Several of the above parameters were signiﬁcantly linked.
Only the main results reaching signiﬁcance are mentioned
here (out of 19 tests carried out). There was a signiﬁcant
associationbetweenantibodytitresandeitherafﬁnity(r¼0.66,
p¼0.0002) or cytophilicity ratio (r¼0.73, p¼0.0005), and this
wastrueforbothIgG1andIgG3(r¼0.92,p¼0.0001andr¼0.66,
p ¼ 0.001, respectively). There was a signiﬁcant correlation
between ADCI activity and the IgG antibody titres (r¼0.68, p¼
0.0001), the cytophilicity ratio (r ¼ 0.76, p ¼ 0.0001), and
cytophilic classes IgG1 and IgG3 (r ¼ 0.75, p ¼ 0.0001 and r ¼
0.39,p¼0.02),asexpectedforaninhibitorymechanismrelying
on antibody-monocyte cooperation. T lymphocyte responses
were signiﬁcantly related with IgG levels (r ¼ 0.47, p ¼ 0.005),
antibody afﬁnity (r¼0.31, p¼0.002), and especially with ADCI
antiparasiteactivity(r¼0.41,p¼0.0001).IFN-cproductionalso
correlated with antibody levels and ADCI activity (r¼0.45, p¼
0.008 and r¼0.37, p¼0.03, respectively).
To avoid accidental correlation between two variables, we
thenperformedamultivariateanalysisusingregression,taking
simultaneously into account all available immunological
parameters; this analysis showed that the antiparasite ADCI
activity was markedly associated with IgG1 levels (F ratio ¼
52.36,p , 0.0001) and cytophilicity (F ratio¼16.59, p¼0.0005),
and marginally associated with afﬁnity of antibodies and
proliferative T cell responses (F ratio ¼ 3.18, p ¼ 0.088 and F
ratio¼3.46, p¼0.077, respectively). It is also remarkable that
ADCI activity was negatively associated with noncytophilic
classesIgG2þIgG4(Fratio¼3.82,p¼0.059)thatdonotbindto
Fc-c receptors. By multiple regression, an increase of one unit
in cytophilicity resulted in a predicted increase of ADCI by
67.5% (p¼0.0001), and increase of one unit in afﬁnity resulted
in an ADCI increase of 42.9% (p¼0.018).
Thus, there was coherence between the immunogenicity of
the vaccine in each volunteer, the type of immune response
induced and the biological effect of the antibodies elicited.
Discussion
The phase-I clinical trial conducted with the ﬁrst MSP3-
based vaccine provided the opportunity to assess not only the
vaccine’s safety and immunogenicity (which were found
satisfactory, particularly with alum as adjuvant [15]) but, more
importantly, to demonstrate its ability to induce antibodies
having a strong anti-parasite effect. This type of immune
response, characteristic of immune adults living in malaria-
endemic regions, requires under natural conditions 10–15 y of
daily exposure to billions of infected red blood cells [4,24,25].
The design of the MSP3-LSP vaccine construct had been
based on studies in humans exposed to priming and
continuous boosting by parasite molecules. This led to the
identiﬁcation of T cell epitopes and dominant B cell epitopes
targeted by cytophilic antibodies that are both associated with
exposure-acquired protection and mediate ADCI in vitro [8].
Immunogenicity recorded in human volunteers is in support
of this immuno-clinical screening strategy. Indeed, the very
good immunogenicity recorded with alum was not predicted
by animal studies, since this adjuvant was ineffective in both
mice and primates with this (unpublished data) and other
antigens[22]. This conﬁrms thatexperimental modelsused for
preclinical development may not predict faithfully the out-
come of immunisations in humans [2].
Cytophilic classes could be readily induced by immunisa-
tion with a short vaccine construct, whereas this takes over a
decade when the corresponding protein is presented by the
intact parasite [11,23]. The correlation with T cell responses
suggests that this may relate to an adequate cytokine proﬁle
secondary to the strong Th cell response induced by four
regions containing Th epitopes. Th1-type activity was
obtained, whereas it is currently believed, mostly based on
experiments in mice, that alum favours Th2-type responses
[26]. The isotype balance may also depend on the character-
istics of the three B cell epitopes included in the LSP
formulation, which were chosen from six regions in the MSP3
C terminus that are preferentially targeted by cytophilic
antibodies [8]. The only difference was that IgG1 predomi-
nated over IgG3 in volunteers, whereas it is the reverse in
endemic area populations [11,23]. However, the isotype
response may differ in populations with distinct genetic
backgrounds; that of Europeans is currently not known, as
they do not acquire protection through natural exposure.
Figure 3. Mean Biological Effect of Antibodies in Either Direct or
Monocyte-Dependent Fashion, at Various Time Points with Each
Adjuvant
Shown are the means 6 standard error of the mean of the effects of sera
from all volunteers in direct growth inhibition assays (used as a control in
each ADCI assay; see Methods) and in monocyte-dependent ADCI assays
(sera from 30 volunteers were analyzed at each time point, i.e., the figure
summarizes results from 90 sera). Triangles, Montanide-adjuvated
vaccine; circles, alum-adjuvated vaccine. Open symbols, direct growth
inhibition by antibodies; solid symbols, monocyte-dependent ADCI
assays. Months 0, 5, and 12: sera collected before immunisation, 1 mo
after the last immunisation, and 12 mo after the first immunisation,
respectively.
DOI: 10.1371/journal.pmed.0020344.g003
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MSP-3 Induces IgG that kill P. falciparumIndeed, the dominant IgG1 heavy chain allotype of Europeans
differs from that of Africans, and the former can mediate
antibody-dependent cellular cytotoxicity, whereas the latter
is less efﬁcient [27–29].
As compared to other phase-I malaria vaccine trials
performed with other vaccine candidates, the results obtained
with MSP-3 stand favourably. Besides safety, T and B cell
responses were within the upper part of the range of those
obtained with other candidates. For instance, the 77%
responders by ELISA to MSP-3 compare well with the 21%
responders to AMA-1 [30]; 16%, 33%, and 16% to MSP-2,
MSP1-190L, and RESA, respectively, in combined immunisa-
tion [31]; 31%–56% to MSP-1, depending on the vaccine dose
[32]; and 72.7%–78% to SPF66 [33,34]. In these studies,
investigations were usually limited to total immunoglobulins
determined by ELISA and, in one case, immunoﬂuorescence
antibody testing, and did not address the isotypic content, the
epitopemapping,orthereactivitywith nativeproteins, except
for immunoﬂuorescence antibody testing, which is of obvious
importance at the time of challenge by the parasite. A major
feature of our study is the inclusion of assays aimed at
providing an indication of the antiparasitic effect of the
induced antibodies. In contrast, reports from previous trials
provide no information about this critical feature of the
experimental immunisation of volunteers, except for one that
found no effect [31].
In contrast, the MSP3-LSP vaccine induced antibodies able
to exert a speciﬁc parasite-killing effect on P. falciparum in two
predictive functional bioassays. Both models have been fully
validated with respect to clinical ﬁndings. The ADCI assay was
positive, with African IgG clinically effective upon passive
transfer in human recipients; conversely, nonprotective IgG
from the recipients, although they contained high titres of
antimalarial antibodies, were ineffective in the assay [23]. This
assay has been further validated by other research groups
[35,36]. The P. falciparum mouse model has been more recently
developed and remains time-consuming and difﬁcult to
employ. Nevertheless, it has been found to mirror drug effects
recorded in patients [21], and in passive immunization
experiments it reproduced all parasitological events recorded
with either protective African IgG or nonprotective control
IgG, upon passive transfer in humans [9].
The killing effect correlated with the ability of antibodies to
bind to the parasite protein in WBs, which was not obtained in
all ELISA-positive volunteers. This is in agreement with
current knowledge about the ADCI mechanism, in which the
effect is triggered by antibodies binding parasite molecules on
the merozoite surface [6]. The killing effect correlated
positively with the content of cytophilic classes of antibodies
and negatively with noncytophilic classes, in agreement with
the monocyte cooperation in ADCI, which requires antibodies
Figure 4. In Vivo Passive Transfer of the Volunteers’ Antibodies in P.
falciparum–Infected Humanised Mice
Shown are representative examples of results obtained by passive
transfer of Western Blot positive sera collected at month 5 (A), or of
control sera (B), and of WB-positive sera collected at month 12 (C).
(A) P. falciparum infected SCID mice received 200 ll of sera delivered IP
from three WB-positive volunteers, collected at month 5, 1 mo after the
last immunisation. Shown are results from two mice that received, first,
normal monocytes (MN), then monocytes with preimmunisation control
sera (month 0), followed by month 5 sera with monocytes (solid arrows
corresponding to volunteers 14 and 16, open and solid squares,
respectively), one mouse receiving first monocytes followed by
monocytes with month 5 serum (dotted arrows, dotted line, open circles)
(B) P. falciparum–infected SCID mice received 200 ll of sera from
controls. Either monocytes followed by monocytes with serum from a
WB-negative volunteer (dotted arrows, dotted line, open circles), or
monocytes with preimmunisation samples from two volunteers followed
by serum alone, repeated twice (plain arrows, solid and open squares).
(C) P. falciparum–infected SCID mice received 200 ll of sera from three
WB-positive volunteers, collected at month 12. All animals received
monocytes first, followed by monocytes with the 12-mo serum, followed
by serum alone. Reproducibility is shown in two animals receiving the
serum from a single donor (volunteer 21, solid squares and open circles).
Transfer of serum alone was ineffective (solid squares, days 6 and 7)
indicating that the strong in vivo antiparasitic effect depends on
monocyte-antibody cooperation.
DOI: 10.1371/journal.pmed.0020344.g004
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MSP-3 Induces IgG that kill P. falciparumbinding to monocyte Fc-c receptors [6,23]. These results
provide an improved rationale for further steps of the clinical
development of MSP3-based vaccines. It is remarkable that a
;40-fold dilution of the volunteers’ antibodies could achieve
in some animals full clearance of a P. falciparum parasitaemia.
Thus, as compared to IgGs from protected African adults, who
have attained the strongest type of protection that can be
achieved in humans [25], the biological effects of vaccine-
induced antibodies were stronger in some volunteers. Indeed,
total African IgG led to a major decrease of parasitaemia but
left a few surviving parasites in the P. falciparum mouse model
[9], consistent with their profound but subtotal effect in Thai
recipients [20]. In contrast, anti-MSP3 antibodies elicited by
LSP immunisation were, at least in some volunteers, able to
sterilize the blood of P. falciparum–infected animals. This is
reminiscent of the stronger effect previously recorded using
anti-MSP3bantibodies,whichhadagreatereffectthanAfrican
IgGs from which they had been afﬁnity-puriﬁed [9]. Similarly,
theinvitroeffectofantibodieselicitedbyMSP3immunisation
in the ADCI assay was on average as strong as or stronger than
that obtained with African immune IgGs.
This indicates that immunisation by a carefully chosen
subunitvaccinecaninduceantibodieswithagreaterbiological
effect than years of exposure to massive amounts of the
parasite itself. It therefore raises the hope that MSP3-based
vaccines could potentially induce stronger clinical protection
than parasite-induced immunisation.
Immune memory has been repeatedly stressed to be a major
concern for malarial vaccines [1]. Thus, another remarkable
feature of anti-MSP3 responses was their very long duration. In
the alum group, high-afﬁnity antibodies reactive with the
parasite protein were prevalent over a year. As a consequence,
antibodies promoting the ADCI killing effect were still present
at 12 mo in the alum group at signiﬁcant levels. Passive transfer
experimentsconﬁrmedthislong-lastingsecretionofantibodies
able to profoundly affect P.falciparum growth in vivo. This long-
term memory is likely to be related to the inclusion of four Th
epitopes for human lymphocytes in the LSP, yielding strong T
cellresponsesin1-ysamples.ResultssuggestanadequateTh-cell
driven maturation of B cells, evident in the alumgroup, leading
to low titres of qualitatively improved antibodies. Results in the
Montanide group were the opposite, with high initial titres
decreasing over time, and in agreement with reports relying on
the same adjuvant with other malarial antigens [37,38]. Our
analysis reveals a marked advantage of alum over Montanide,
which is encouraging, since it is also better tolerated. This
challenges the current concept that strong and somewhat toxic
adjuvants are unavoidably required, and emphasises the
importance of the choice of the antigen.
The vaccine formulation employed here has very attractive
biological features, however remains suboptimal. Although
strong T cell responses were induced in all volunteers [15],
antibodies were not detectable in 23% of them, and antibodies
induced in some volunteers failed to react with the parasite
protein and reacted with only two of the three B cell epitopes
included in the LSP. We had decided in favour of a relatively
short synthetic polypeptide vaccine formulation for our ﬁrst
clinical trial, as it is faster to implement than recombinant
vaccines. Results support this approach, which led to critical
informationthatcouldnotbegatheredinexperimentalmodels
(e.g.,thevalueofalum,durationofimmuneresponses,reactivity
with the parasite protein, and bioactivity of human antibodies).
These limitations are likely to be overcome by second-
generation,larger recombinants coveringthe whole C-terminal
conserved region, because they will contain more epitopes, and
longer polypeptides are usually more immunogenic. It also
remains to be seen if the vaccine will be as effective in children
from malaria-endemic areas as it was in naive adults.
It has been reported that P. falciparum, with part of the gene
encoding MSP3 knocked out, could remain viable [39]; this
could be a matter of concern for MSP3-based vaccine
formulations. However, recent results also show that other
genes, such as that encoding MSP6, express epitopes that are
fullycross-reactivewithMSP3andaretargetsofMSP3-induced
antibodies, mediating a monocyte-dependent, antibody-de-
pendent,growth-inhibitoryeffectofequalmagnitudetoMSP3
epitopes [40]. In this manner, the parasite expresses several
identical target antigens to ADCI-mediating antibodies.
The main limitations to malaria vaccine development are
currently thought to be high polymorphism in the regions of
immunological interest, low antigenicity without the use of
powerfulandhencetoxicadjuvants,shortdurationofimmune
responses, and lack of bioassays able to reﬂect protection and
hence to guide preclinical steps [1]. In this initial trial of a
MSP3-based vaccine in humans, preliminary results in 30
volunteers indicate that even low doses of MSP3-LSP injected
with simple adjuvants readily induced antibodies of cytophilic
classes directed to fully conserved epitopes, induced long-
lasting effects, and showed strong biological activity against P.
falciparum erythrocytic stages. Within the limitation of the
actual predictive value of these biological assays, which can be
conﬁrmed only under Phase II trials, the results indicate that
this vaccine can overcome a large number of the identiﬁed
bottlenecks.
Supporting Information
Text S1. Present Status of the P. falciparum SCID Mouse Model
Found at DOI: 10.1371/journal.pmed.0020344.sd001 (448 KB PDF).
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Patient Summary
Background Malaria causes a huge global disease burden, and a vaccine
is urgently needed. The disease is caused by the Plasmodium parasite,
which is transmitted to humans by mosquito bites. Vaccines would
educate and prepare the immune system so that it could attack and
destroy parasites that get transmitted before they can infect and destroy
human blood cells and cause people to get sick. Another goal for a
vaccine is that the immune system maintains the capability to fight off
an infection for a while so that the vaccination need not be repeated
often.
Why Was This Study Done? This group of researchers works on a
particular component from the parasite surface called MSP3. They chose
MSP3 as a vaccine candidate because they discovered, after studying
populations infected by the parasite, that this molecule triggered an
immune response that could eliminate the parasite. They now wanted to
test MSP3 in humans.
What Did the Researchers Do and Find? They mixed MSP3 together
with one of two nonspecific immune boosters and injected 30 healthy
volunteers with different amounts of MSP3 in combination with one of
the two boosters. The volunteers received three injections each over the
course of several months. Like with all new medications that are given to
humans for the first time, the most important question was that of
safety, and the researchers found that the experimental vaccine was safe.
They also found that it generated a strong general immune response in
the volunteers, which is what vaccines are meant to do. But were the
immune responses functional? The ultimate test would be to see
whether they could fend off a malaria infection, but for vaccines at such
an early stage of development that experiment is much too risky and
therefore unethical. Instead, the researchers isolated the immune
components from the blood of the vaccinated volunteers and examined
them in two different functional tests. Both tests showed that 60% of the
volunteers had vaccine-induced immune responses that were quite
potent against the parasite. In people who received MSP3 with alum as a
booster, these responses lasted for at least 12 months after the last
injection.
What Does This Mean? These results are certainly encouraging and
suggest that an MSP3-based vaccine should be explored further. Future
studies need to address the questions of why only 60% of injected
volunteers mounted a strong immune response, whether the parasite
could develop resistance to an immune response directed mainly against
MSP-3, and whether the immune responses that look promising in the
functional assays used here actually confer protection when immunized
individuals are exposed to malaria.
Where Can I Find More Information Online? Malaria Foundation
International:
http://www.malaria.org/
Malaria Vaccine Initiative:
http://www.malariavaccine.org/
General information on malaria can be found on the World Health
Organization Web site:
http://www.who.int/malaria
List of experimental malaria vaccines presently under development:
http://www.who.int/vaccine_research/documents/malaria_table.pdf
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